News | March 7, 2024

CuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data with CST-2032/CST-107 in Patients with Alzheimer’s or Parkinson’s Disease at AD/PD™ 2024 International Conference Drug Combination’s Unique Mechanism of Action Enables Reactivation...

News | March 5, 2024

New Data Demonstrate Sunbird Bio’s APEX Diagnostic Test Accurately Differentiates Key Alzheimer’s Disease Biomarker in Blood– Blood-based diagnostic effectively discriminated between patients who were positive versus negative for amyloid beta on PET scans – – Data...

News | March 5, 2024

Cleerly® Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging SystemCompany’s AI-enabled technology for future heart attack risk assessment accepted into FDA’s TAP Pilot and to be validated in landmark TRANSFORM trial DENVER – March 5, 2024...

News | March 11, 2024

Merck Completes Acquisition of Harpoon Therapeutics, Inc. Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager RAHWAY, N.J.–(BUSINESS...

News | January 8, 2024

Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors...